The initiation of GLP-1 receptor agonists is associated with modest shifts away from ultraprocessed foods and toward items with fewer calories and smaller amounts of carbs, sugar, and saturated fat.

Use of liraglutide or semaglutide therapy does not increase risk for thyroid cancer among patients with type 2 diabetes or obesity.

Please provide your email address to receive an email when new articles are posted on . Of 145,410 adults who began a GLP-1 drug, 76 developed thyroid cancer over a mean 3.9 years of follow-up. Risk ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SGLT2 inhibitors cut the risk for adverse CV outcomes ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss ...

Since their introduction 20 years ago, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have revolu­tionised the treatment of diabetes and obesity. Known for their immunomodulatory and ...

The desire to lose weight is nothing new, and neither are medications to help. While there's a massive GLP-1 craze, these are weight loss medications have have existed prior to its release.

Patients with diabetes being managed with GLP-1R agonists can expect a slight decrease in intraocular pressure. Glucagon-like peptide-1 receptor (GLP-1R) agonist therapy used for the treatment of ...

Following ablation for AF, GLP-1 agonist therapy is associated with decreased risk for AF recurrence in patients with type 2 diabetes. Glucagon-like peptide-1 receptor (GLP-1) agonist use is ...

USA: Researchers have found in a new study that, over two years, bariatric surgery resulted in substantially greater fat-mass ...